Opinion|Videos|April 8, 2025
Tildrakizumab in Practice: Adherence and Clinical Takeaways
Author(s)Aaron Farberg, MD
An expert discusses how health care provider administration may improve adherence to tildrakizumab. The meta-analysis confirms its real-world efficacy, safety, and quality of life benefits, supporting clinical use. These findings may influence payer decisions by reinforcing its value and long-term effectiveness in psoriasis care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Since tildrakizumab is administered by health care providers, do you think this leads to better adherence of the therapy?
- What are your main takeaways from this abstract, and how will you carry this over to your clinical practice?
- How do you believe these abstract results will influence payer decisions?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently
2
Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains
3
Defunding Co-Payment Assistance Disrupted nAMD Care
4
Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer
5